Brief: Qsam Biosciences Signs Term Sheet To Be Acquired By Telix Pharmaceuticals Receives $2 Million Pre-Closing Collaboration And Option Fee
14/11/2023 12:32
Nov 14 (Reuters) - Qsam Biosciences Inc QSAM.PK :
* QSAM BIOSCIENCES SIGNS TERM SHEET TO BE ACQUIRED BY TELIX
PHARMACEUTICALS; RECEIVES $2 MILLION PRE-CLOSING COLLABORATION
AND OPTION FEE
* QSAM BIOSCIENCES INC- IF ACQUISITION DOES NOT CLOSE,
COLLABORATION FEE WILL BE CONVERTED TO COMPANY COMMON STOCK AT A
PRICE OF 6.70 PER SHARE
* QSAM BIOSCIENCES INC - TELIX IS EXPECTED TO PAY A TOTAL OF
US$33.1 MILLION IN TELIX STOCK
Source text for Eikon: ID:nGNX5ggFQr
Further company coverage: QSAM.PK
((Reuters.Briefs@thomsonreuters.com))
Recent news on Qsam Biosciences
See all newsBrief: QSAM Biosciences Signs Definitive Agreement To Be Acquired By Telix Pharmaceuticals
Brief: Qsam Biosciences Says Co Granted Telix An Additional 30 Days Under Exclusivity Period To Complete Its Due Diligence
Brief: Qsam Biosciences Signs Term Sheet To Be Acquired By Telix Pharmaceuticals Receives $2 Million Pre-Closing Collaboration And Option Fee
Brief: Telix Pharmaceuticals Announces Proposed Acquisition Of QSAM Biosciences
Brief: Qsam Biosciences Provides Update To Shareholders On Phase 1 Progress And Preliminary Clinical Data